ME02806B - Protutijela protiv csf-1r - Google Patents
Protutijela protiv csf-1rInfo
- Publication number
- ME02806B ME02806B MEP-2017-174A MEP17417A ME02806B ME 02806 B ME02806 B ME 02806B ME P17417 A MEP17417 A ME P17417A ME 02806 B ME02806 B ME 02806B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- antibody
- csf
- seq
- intended
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Protutijelo koje se specifično veže na varijantu ljudskog CSF-1R (SEQ ID NO. 15), naznačeno time što sadrži teški lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:9 i laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:10.
2. Protutijelo koje se specifično veže na ljudski CSF-1R (SEQ ID NO. 16), naznačeno time što sadrži teški lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:9 i laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:10.
3. Protutijelo u skladu s patentnim zahtjevima 1-4 ili 2, naznačeno time što sadrži dva teška lanca, od kojih svaki sadrži aminokiselinski slijed sa SEQ ID NO:9. i dva laka lanca, od kojih svaki sadrži aminokiselinski slijed sa SEQ ID NO:10.
4. Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što dodatno sadrži dodatno farmaceutsko sredstvo.
6. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi kao medikament.
7. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka.
8. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 7, naznačeno time što je rak leukemija, rak dojke, rak endometrija, rak prostate, rak jajnika, kolorektalni rak, hepatocelularni rak, rak bubrega, multipli mielom ili Hodgkinov limfom.
9. Protutijelo je namijenjeno upotrebi u skladu s patentnim zahtjevom 8, naznačeno time što je rak leukemija, rak dojke, rak endometrija ili rak prostate.
10. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 9, naznačeno time što je rak leukemija, rak dojke ili rak prostate.
11. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevima 6-10, naznačeno time što se protutijelo primijenjuje prije, za vrijeme, uglavnom istodobno s ili nakon početka terapije drugim antikanceroznim liječenjem.
12. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što se navedeno antikancerozno liječenje bira iz skupine koju čine antiangiogenetsko sredstvo, kemoterapijsko sredstvo i antineoplastično sredstvo.
13. Protutijelo, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačeno time što se navedeno antineoplastično sredstvo bira iz skupine koju čine docetaksel, paklitaksel, Herceptin® i doksorubicin.
14. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka kod pacijenta koja se sastoji u mjerenju razine CSF-1 u uzorku uzetom iz pacijenta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, i te u primjeni na pacijentu protutijela u skladu s bilo kojim od patentnih zahtjeva 1-3 ako su razine CSF-1 više od razina CSF-1 nađenih kod kontrolne populacije.
15. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka kod pacijenta koja se sastoji u mjerenju razine IL-34 u uzorku uzetom iz pacijenta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, te u primjeni na pacijentu protutijela u skladu s bilo kojim od patentnih zahtjeva 1-3 ako su razine IL-34 više od razina IL-34 nađenih kod kontrolne populacije.
16. Postupak određivanja je li subjekt koji ima rak kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R, gdje je navedeno protutijelo protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što se sastoji u: određivanju razine CSF-1 ili IL-34, ili oba, ex vivo ili in vitro u uzorku iz subjekta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, gdje porast razine CSF-1, ili IL-34, ili oba, u usporedbi s razinom CSF-1, ili IL-34, ili oba, kod pojedinca koji ne boluje od raka, ukazuje da je subjekt kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 | |
| EP11713416.3A EP2552966B1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
| PCT/US2011/030148 WO2011123381A1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02806B true ME02806B (me) | 2018-01-20 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-174A ME02806B (me) | 2010-04-01 | 2011-03-28 | Protutijela protiv csf-1r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (me) |
| EP (2) | EP2552966B1 (me) |
| JP (1) | JP5767310B2 (me) |
| KR (1) | KR101439719B1 (me) |
| CN (1) | CN102834414B (me) |
| AR (1) | AR080698A1 (me) |
| AU (1) | AU2011232850B2 (me) |
| BR (1) | BR112012024564A2 (me) |
| CA (1) | CA2795081C (me) |
| CY (1) | CY1119324T1 (me) |
| DK (1) | DK2552966T3 (me) |
| EA (1) | EA021600B1 (me) |
| ES (1) | ES2640909T3 (me) |
| HR (1) | HRP20171153T1 (me) |
| HU (1) | HUE036379T2 (me) |
| IL (1) | IL222222A (me) |
| JO (1) | JO3291B1 (me) |
| LT (1) | LT2552966T (me) |
| ME (1) | ME02806B (me) |
| MX (1) | MX2012011234A (me) |
| NZ (1) | NZ602621A (me) |
| PL (1) | PL2552966T3 (me) |
| PT (1) | PT2552966T (me) |
| RS (1) | RS56219B1 (me) |
| SG (1) | SG183829A1 (me) |
| SI (1) | SI2552966T1 (me) |
| TW (1) | TWI402078B (me) |
| UA (1) | UA111818C2 (me) |
| WO (1) | WO2011123381A1 (me) |
| ZA (1) | ZA201206926B (me) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010329934B2 (en) | 2009-12-10 | 2015-05-14 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human CSF1R extracellular domain 4 and their use |
| WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX355418B (es) | 2010-05-04 | 2018-04-18 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| EP2812355A4 (en) * | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| EA035336B1 (ru) | 2013-12-09 | 2020-05-29 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способ лечения связанного со старением когнитивного расстройства или заболевания |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| KR20230086809A (ko) | 2014-06-23 | 2023-06-15 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법 |
| BR112017008914A2 (pt) | 2014-10-29 | 2018-01-16 | Five Prime Therapeutics, Inc. | método para tratar câncer, composição e uso da composição |
| KR20170096187A (ko) | 2014-12-22 | 2017-08-23 | 파이브 프라임 테라퓨틱스, 인크. | Pvns를 치료하기 위한 항-csf1r 항체 |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| CN113940996A (zh) | 2015-05-27 | 2022-01-18 | Ucb生物制药私人有限公司 | 用于治疗神经系统疾病的方法 |
| AU2016279804B2 (en) | 2015-06-15 | 2019-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| US20180222985A1 (en) * | 2015-06-24 | 2018-08-09 | Hoffmann-La Roche Inc. | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| EP3973988A1 (en) | 2015-11-04 | 2022-03-30 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| US20180291107A1 (en) * | 2015-11-24 | 2018-10-11 | Eli Lilly And Company | Combination therapy for cancer |
| CA3005932A1 (en) * | 2015-11-25 | 2017-06-01 | Nogra Pharma Limited | Il-34 antisense oligonucleotides and methods of using same |
| WO2017189919A2 (en) | 2016-04-28 | 2017-11-02 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| TW201825519A (zh) | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| WO2018115051A1 (en) * | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| UA127828C2 (uk) | 2017-04-26 | 2024-01-17 | Алкахест, Інк. | Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень |
| JP7537874B2 (ja) | 2017-05-19 | 2024-08-21 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 併用療法 |
| BR112020003533A2 (pt) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
| BR112020004879A2 (pt) | 2017-09-13 | 2020-09-15 | Five Prime Therapeutics, Inc. | métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer |
| US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| CN111741978A (zh) | 2018-02-21 | 2020-10-02 | 戊瑞治疗有限公司 | B7-h4抗体制剂 |
| GB201803226D0 (en) * | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| EP3759142A1 (en) | 2018-03-02 | 2021-01-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| BR112020018709A2 (pt) * | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| KR20210049106A (ko) | 2018-07-27 | 2021-05-04 | 알렉터 엘엘씨 | 항-siglec-5 항체 및 이의 사용 방법 |
| WO2020069372A1 (en) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| CA3115308A1 (en) | 2018-10-26 | 2020-04-30 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
| EP3894014A4 (en) * | 2018-12-13 | 2022-04-20 | Development Center for Biotechnology | Anti-human csf-1r antibody and uses thereof |
| US20220137054A1 (en) * | 2019-03-05 | 2022-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New biomarkers and biotargets in renal cell carcinoma |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| AU2020283742A1 (en) * | 2019-05-24 | 2021-09-16 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| WO2021058718A1 (en) | 2019-09-26 | 2021-04-01 | Roche Diagnostics Gmbh | Anti-csf-1r antibody |
| WO2021076942A1 (en) * | 2019-10-17 | 2021-04-22 | National Health Research Institutes | Use of succinate as biomarker in diagnosis and treatment of cancers |
| WO2021087105A1 (en) | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| EP4073100A4 (en) | 2019-12-09 | 2024-02-14 | Syndax Pharmaceuticals, Inc. | ANTIBODIES FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
| WO2024238787A1 (en) | 2023-05-17 | 2024-11-21 | Syndax Pharmaceuticals, Inc. | Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Ｉｌ‐２レセプター特異的キメラ抗体 |
| ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| EP1572106B1 (en) * | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| WO2006096461A2 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
| MX2010001918A (es) * | 2007-08-21 | 2010-03-11 | Amgen Inc | Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino. |
| CN101970496B (zh) * | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko not_active Expired - Fee Related
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/en active
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en not_active Ceased
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02806B (me) | Protutijela protiv csf-1r | |
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| JP2013529183A5 (me) | ||
| Yamamoto et al. | Latest advances in extracellular vesicles: from bench to bedside | |
| Zhang et al. | Near-infrared light irradiation induced mild hyperthermia enhances glutathione depletion and DNA interstrand cross-link formation for efficient chemotherapy | |
| Adamska et al. | ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? | |
| Chen et al. | Advances in the development of aptamer drug conjugates for targeted drug delivery | |
| JP2020182492A5 (me) | ||
| Guion-Dusserre et al. | FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma | |
| JP2017514143A5 (me) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2019534034A5 (me) | ||
| Damia et al. | The pharmacological point of view of resistance to therapy in tumors | |
| JP2014530215A5 (me) | ||
| FI4241849T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2011157397A5 (me) | ||
| JP2013511288A5 (me) | ||
| JP2012019790A5 (me) | ||
| JP2007504280A5 (me) | ||
| RU2014138420A (ru) | Антитела против sez6 и способы их применения | |
| JP2016520082A5 (me) | ||
| RU2013138177A (ru) | Антитела, действующие селективно на клетки с повышенной плотностью мишени рецептор эпидермального фактора роста (egfr) | |
| Zhang et al. | A multifunctional Fe-EGCG@ RSL3 nanomedicine synergizes ferroptosis induction and tumor microenvironment remodeling for enhanced bladder cancer immunotherapy | |
| RU2017136863A (ru) | Способы лечения рака легкого | |
| RU2013114783A (ru) | Anti-с-мет антитела и способы их применения |